GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (XSWX:RLF) » Definitions » Cash Flow for Lease Financing

Relief Therapeutics Holding (XSWX:RLF) Cash Flow for Lease Financing : CHF0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Relief Therapeutics Holding Cash Flow for Lease Financing?

Relief Therapeutics Holding's Cash Flow for Lease Financing for the six months ended in Jun. 2024 was CHF0.00 Mil. Relief Therapeutics Holding's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Jun. 2024 was CHF0.00 Mil.

Compared with last quarter (CHF0.00 Mil in Dec. 2023 ), Relief Therapeutics Holding's Cash Flow for Lease Financing remained the same in Jun. 2024 (CHF0.00 Mil).

Relief Therapeutics Holding Cash Flow for Lease Financing Historical Data

The historical data trend for Relief Therapeutics Holding's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding Cash Flow for Lease Financing Chart

Relief Therapeutics Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow for Lease Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.19 -0.39 -

Relief Therapeutics Holding Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.18 -0.21 -0.34 - -

Relief Therapeutics Holding Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relief Therapeutics Holding Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Relief Therapeutics Holding Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (XSWX:RLF) » Definitions » Cash Flow for Lease Financing
Comparable Companies
XSWX:EVE XSWX:SPEX XSWX:OBSN XSWX:ADXN XSWX:KNRS XSWX:NWRN XSWX:MOLN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY
Traded in Other Exchanges
RLFTY:USA RLFTF:USA RLFz:UK 0QKQ:UK
Address
Avenue de Secheron 15, Geneva, CHE, 1202
Website
https://www.relieftherapeutics.com
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development such as RLF-TD011, and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast among others. Geographically the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.

Relief Therapeutics Holding Headlines

No Headlines